TikTok CEO says China-based ByteDance employees still have access to some U.S. data
TikTok CEO Shou Zi Chew told U.S. lawmakers that China-based employees at its parent company ByteDance may still have access to some U.S. data from the app.
Judge cites Trump’s past verbal attacks in using anonymous jury for rape defamation case
Donald Trump is being sued for allegedly raping and defaming the writer E. Jean Carroll, who says he attacked her in a New York department store.
TikTok CEO set for grilling in House hearing. But U.S. lawmakers also face questions
While TikTok’s CEO will be in the hot seat, lawmakers will also face difficult questions about how best to deal with potential harms from tech firms.
Orange County dismisses domestic violence charges against ‘Rick and Morty’ co-creator Justin Roiland
In a statement to NBC News, an attorney for Roiland said the Orange County District Attorney’s Office conducted a “thorough review of the facts.”
Barclays says shares of this mall operator could rebound 20% because of its high income customers
The firm said the stock is at an attractive entry point given the firm’s compelling growth and demographics.
This little-known biotech stock developing treatments for blood disorders could jump 80%, BMO says
The firm initiated coverage of this stock with an outperform rating and a $40 price target.
Ford’s EV business lost $2 billion in 2022, offset by big profits in fleet and legacy units
The financials are the first detailed look at EV profitability as Ford unveils a new financial reporting structure.
Oppenheimer downgrades Coinbase, cites ‘unhealthy regulatory climate’ after Wells notice
The firm said there are troubling signals for the digital asset sector following the collapse of Silicon Valley Bank and Signature Bank and other banks.
Cruise robotaxis blocked a road in San Francisco after a storm downed trees and wires
A witness told CNBC the driverless Cruise vehicles did not appear to detect and avoid the caution tape and bus wires, and instead became “tangled in them.”
FDA advisors vote against effectiveness of Biogen’s ALS drug for rare and aggressive form of the disease
FDA advisors voted against the effectiveness of Biogen’s investigational ALS drug, which could become the first to target a genetic cause of the disease.
